Inhibitors

RO5126766; RO-5126766; Avutometinib; Ro 5126766; N-(3-Fluoro-4-{[4-Methyl-2-Oxo-7-(Pyrimidin-2-Yloxy)-2h-Chromen-3-Yl]Methyl}Pyridin-2-Yl)-N'-Methylsulfuric Diamide; Sulfamide, N-(3-Fluoro-4-((4-Methyl-2-oxo-7-(2-Pyrimidinyloxy)-2H-1-Benzopyran-3-yl)Methyl)-2-Pyridinyl)-N'-Methyl-; 3-[(2-((N-Methylsulfamoyl)Amino)-3-Fluoropyridin-4-yl)Methyl]-4-Methyl-7-(Pyrimidin-2-Yloxy)-Chromen-2-one; 3-[[3-Fluoro-2-(Methylsulfamoylamino)Pyridin-4-yl]Methyl]-4-Methyl-7-Pyrimidin-2-Yloxychromen-2-one; N-(3-Fluoro-4-((4-Methyl-2-OXO-7-(Pyrimidin-2-Yloxy)-2H-Chromen-3-YL)Methyl)Pyridin-2-YL)-N'-Methylsulfamide

N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-{[2-(Sulfamoylamino)Ethyl]Amino}-1,2,5-Oxadiazole-3-Carboximidamide; (Z)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-[2-(Sulfamoylamino)Ethylamino]-1,2,5-Oxadiazole-3-Carboxamidine; 1,2,5-Oxadiazole-3-Carboximidamide, 4-((2-((Aminosulfonyl)Amino)Ethyl)Amino)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-, (C(Z))-; N'-(3-Bromo-4-Fluorophenyl)-N-Hydroxy-4-((2-(Sulfamoylamino)Ethyl)Amino)-1,2,5-Oxadiazole-3-Carboximidamide; N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-{[2-(Sulfamoylamino)Ethyl]Amino}-1,2,5-Oxadiazole-3- Carboxi; (3E)-3-[(3-Bromo-4-Fluoroanilino)-Nitrosomethylidene]-4-[2-(Sulfamoylamino)Ethylamino]-1,2,5-Oxadiazole; (Z)-N-(3-Bromo-4-Fluorophenyl)-N Inverted Exclamation mark -Hydroxy-4-[[2-(Sulfamoylamino)Ethyl]Amino]-1,2,5-Oxadiazole-3-Carboxamidine; (Z)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-((2-(Sulfamoylamino)Ethyl)Amino)-1,2,5-Oxadiazole-3-Carboximidamide; (Z)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-(2- (Sulfamoylamino)Ethylamino)-1,2,5-Oxadiazole-3-Carboxamidine; (Z)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-(2-(Sulfamoylamino)Ethylamino)-1,2,5-Oxadiazole-3-Carboximidamide; 1,2,5-Oxadiazole-3-Carboximidamide, 4-((2-((Aminosulfonyl)Amino)Ethyl)Amino)-N'-(3-Bromo-4-Fluorophenyl)-N-Hydroxy-; 1,2,5-Oxadiazole-3-Carboximidamide, 4-((2-((Aminosulfonyl)Amino)Ethyl)Amino)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-; 1,2,5-Oxadiazole-3-Carboximidamide, 4-[[2-[(Aminosulfonyl)Amino]Ethyl]Amino]-N-(3-Bromo-4-Fluorophenyl)-N-Hydroxy-, [C(Z)]-; 4-({2-[(Aminosulfonyl)Amino]Ethyl}Amino)-N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-1,2,5-Oxadiazole-3-Carboximidamide; N-(3-Bromo-4-Fluoro-Phenyl)-N'-Hydroxy-4-[2-(Sulfamoylamino)Ethylamino]-1,2,5-Oxadiazole-3-Carboxamidine; N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-[[2-(Sulfamoylamino)Ethyl]Amino]-1,2,5-Oxadiazole-3-Carboxamidine; N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-[2-(Sulfamoylamino)Ethylamino]-1,2,5-Oxadiazole-3-Carboxamidine; N-(3-Bromo-4-Fluorophenyl)-N'-Hydroxy-4-{[2-(Sulfamoylamino)Ethyl]Amino}-1,2,5-Oxadiazole-3- Carboximidamide

BC-3781 Acetate; Acetic acid;[(1S,2R,3S,4S,6R,7R,8R,14R)-4-Ethenyl-3-Hydroxy-2,4,7,14-Tetramethyl-9-oxo-6-Tricyclo[5.4.3.01,8]Tetradecanyl] 2-[(1R,2R,4R)-4-Amino-2-Hydroxycyclohexyl]Sulfanylacetate; BC-3781.Ac

Lupkynis; Luveniq; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-Hydroxy-2-Methylhepta-4,6-Dienyl]-1,4,7,10,12,15,19,25,28-Nonamethyl-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-di(Propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-Undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-Undecone; Voclera; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-((1R,2R,E)-1-Hydroxy-2-Methylhepta-4,6-dien-1-yl)-6,9,18,24-Tetraisobutyl-3,21-Diisopropyl-1,4,7,10,12,15,19,25,28-Nonamethyl-1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-Undecaone; Cyclosporin A, 6-((2S,3R,4R)-3-Hydroxy-4-Methyl-2-(Methylamino)-6,8-Nonadienoic acid)-; (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-Ethyl-33-[(1R,2R,4E)-1-Hydroxy-2-Methylhepta-4,6-dien-1-yl]-1,4,7,10,12,15,19,25,28-Nonamethyl-6,9,18,24-Tetrakis(2-Methylpropyl)-3,21-bis(Propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-Undecaazacyclotritriacontan-2,5,8,11,14,17,20,23,26,29,32-Undecone; 1,11-Anhydro[L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl- N-Methyl-L-Valyl-[(2S,3R,4R,6E)-3-Hydroxy-4-Methyl- 2-(Methylamino)nona-6,8-Dienoyl][(2S)-2-Aminobutanoyl]- N-Methylglycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucine]; Cyclo (((E,Z)-(2S,3R,4R)-3-Hydroxy-4-Methyl-2-(Methylamino)NONA-6,8-Dienoyl)-L-2-Aminobytyrl-N-Methyl-Glycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucyl-L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl-N-Methyl-L-Valyl); Cyclo(L-Alanyl-D-Alanyl-N-Methyl-L-Leucyl-N-Methyl-L-Leucyl-N-Methyl-L-Valyl- ((2S,3R,4R,6E)-3-Hydroxy-4-Methyl-2-(Methylamino)NONA-6,8-Dienoyl)-(2S)-2- Aminobutanoyl-N-Methylglycyl-N-Methyl-L-Leucyl-L-Valyl-N-Methyl-L-Leucyl); Cyclosporin A, 6-((2S,3R,4R,6E)-3-Hydroxy-4-Methyl-2-(Methylamino)-6,8- Nonadienoic ACID)-

Trilaciclib Dihydrochloride; Trilaciclib 2HCl; G1T28 Hydrochloride; G1T28 Dihydrochloride; Trilaciclib (Hydrochloride); 2'-((5-(4-Methylpiperazin-1-yl)Pyridin-2-yl)Amino)-7',8'-Dihydro-6'Hspiro(Cyclohexane-1,9'-Pyrazino(1',2':1,5)Pyrrolo(2,3-d)Pyrimidin)-6'-one Dihydrochloride; 4-[[5-(4-Methylpiperazin-1-yl)Pyridin-2-yl]Amino]Spiro[1,3,5,11-Tetrazatricyclo[7.4.0.02,7]Trideca-2,4,6,8-Tetraene-13,1'-Cyclohexane]-10-one;Dihydrochloride; Spiro(Cyclohexane-1,9'(6'H)-Pyrazino(1',2':1,5)Pyrrolo(2,3-d)Pyrimidin)-6'-one, 7',8'-Dihydro-2'-((5-(4-Methyl-1-Piperazinyl)-2-Pyridinyl)Amino)-, Hydrochloride (1:2); Trilaciclib Hydrochloride(G1T28); 12'-{[5-(4-Methylpiperazin-1-yl)Pyridin-2-yl]Amino}-2',5',11',13'-Tetraazaspiro[Cyclohexane-1,3'-Tricyclo[7.4.0.0(2),]Tridecane]-1'(9'),7',10',12'-Tetraen-6'-one Dihydrochloride